Amylyx Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $3.2B
- as of Sep 30, 2026
- Shares Outstanding
- 111.4M
- Free Float
- 79.8%
Income Statement
- Revenue
- $0
- Operating Income
- -$153.3M
- Net Income
- -$144.7M
- EBITDA
- -$152.8M
Cash Flow
- Free Cash Flow
- -$123.5M
- FCF Yield
- -3.8%
- Owner FCF Yield
- -4.7%
Balance Sheet
- Cash & Equivalents
- $226.7M
Returns & Capital
- SBC, 3Y Avg
- $32.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$123.5M | — |
| FY2024 | $87.4M | -$167.8M | -192.1% |
| FY2023 | $380.8M | $10.7M | 2.8% |
| FY2022 | $22.2M | -$182.4M | -820.5% |
| FY2021 | $285,000 | -$75.2M | -26369.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back